What question did this study set out to answer?

The aim is to explore the pathological mechanisms and animal models used in studying adriamycin-induced myocardial injury.

March 28, 2026

Research Progress on Adriamycin-Induced Myocardial Injury: Pathological Mechanism and Animal Model.

Key Result

Adriamycin-induced cardiotoxicity primarily manifests as structural and functional damage to myocardial cells, which can lead to severe cardiovascular diseases such as heart failure.

Key Points

The aim is to explore the pathological mechanisms and animal models used in studying adriamycin-induced myocardial injury.
Review of recent findings on adriamycin and its cardiotoxicity.
Analysis of animal models used to study myocardial injury.
Discussion of therapeutic drugs for combating adriamycin-induced damage.
Adriamycin causes structural and functional damage to myocardial cells.
Identified key pathological mechanisms underlying cardiotoxicity.
Highlighted the need for effective treatment strategies and reliable animal models.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Adriamycin is an anthracycline chemotherapy drug used in cancer treatment,and its cardiotoxicity primarily manifests as structural and functional damage to myocardial cells,which can lead to severe cardiovascular diseases such as heart failure.This article reviews recent advances in adriamycin-induced myocardial injury,focusing on its pathological mechanisms,potential therapeutic drugs,and commonly used animal models,to provide a research basis and intervention strategies for developing effective treatments.

Bookmark

Cite This Study

Tao et al. (Sun,) reported a other. Adriamycin-induced cardiotoxicity primarily manifests as structural and functional damage to myocardial cells, which can lead to severe cardiovascular diseases such as heart failure.

synapsesocial.com/papers/69c771838bbfbc51511e16bf https://doi.org/https://doi.org/10.3881/j.issn.1000-503x.16565